Keyword: Bristol-Myers Squibb
A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.
Well, let’s start with the obvious, a pattern that has been set for a good few years now: There were no M&A deals.
As Bristol-Myers Squibb looked to subsume Big Biotech Celgene, its chief scientific officer Thomas Lynch decided to walk.
Pfizer Chairman Read to take Viatris board seat; Bristol's Biondi bolts; Ipsen CEO Meek takes over new company.
Inrebic is the first new treatment in nearly a decade approved to treat myelofibrosis.
Days after leaving Bristol-Myers Squibb (and amid its big merger deal with Celgene), former dealmaker Paul Biondi has landed at a major biotech VC.
Bristol-Myers and Acceleron are also seeking approval in myelodysplastic syndromes, a group of cancers in which immature blood cells in the bone marrow don’t fully develop and become healthy blood cells. If Reblozyl nabs a second nod, analysts figure it could hit $2 billion in yearly sales.
2019 was something of an annus horribilis when it came to trying to find new therapies for aggressive brain cancer glioblastoma multiforme, and one of the biggest disappointments came from the failure of an immuno-oncology approach to the disease.
This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.
In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.